UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
August 18, 1999
---------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On August 18, 1999, the Company issued a press release
announcing that its Board of Directors has declared
dividends on the Company's 8 1/2% Series A Convertible
Exchangeable Preferred Stock and the Company's 8 1/2% Series
B Convertible Pay-in-Kind Preferred Stock.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibit
20 Press release of the Company dated
August 18, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By: /s/BRADFORD T. SMITH
------------------------------
Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer
Date: August 31, 1999
<PAGE>
2
Laboratory Corporation of America-Registered Trademark-Holdings
358 South Main Street
Burlington, NC 27215
FOR IMMEDIATE RELEASE
- ---------------------
Contact: 336-584-5171 Shareholder Direct: 800-LAB-0401
Media - Cynthia Jay, Ext. 5052 www.labcorp.com
Investors - Pamela Sherry, Ext. 4855
LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK- DECLARES
PREFERRED STOCK DIVIDENDS
Burlington, NC, August 18, 1999 - Laboratory Corporation of America-Registered
Trademark-Holdings (LabCorp-Registered Trademark-) (NYSE: LH) today announced
that its Board of Directors has declared a dividend of $1.0625 per share on the
Company's 8 1/2 percent Series A Convertible Exchangeable Preferred
Stock (Series A Preferred Stock), payable in cash. The Board has
also declared a dividend of $1.0625 per share on the Company's 8 1/2
percent Series B Convertible Pay-in-Kind Preferred Stock (Series B
Preferred Stock), payable in shares of Series B Preferred Stock at
the rate of 0.02125 shares per share of Series B Preferred Stock
held. No fractional shares of Series B Preferred Stock will be
issued, so that the number of shares to be paid as a dividend on the
Series B Preferred Stock will be rounded to the nearest whole number
of shares. The dividends will be payable on September 30, 1999, for
each issued and outstanding share of Series A and B Preferred Stock
to stockholders of record on September 17, 1999, and will cover the
dividend period from July 1, 1999, to September 30, 1999, at an
equivalent annualized rate of $4.25 per share.
Laboratory Corporation of America-Registered Trademark-Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory with
annual revenues of $1.6 billion in 1998. With 18,000 employees and
over 100,000 clients nationwide, the company offers more than 2,000
clinical tests, ranging from simple blood analyses to more sophisticated
technologies. Included in LabCorp's network of 25 major laboratories are
three Centers of Excellence. The Center for Molecular Biology and Pathology,
in Research Triangle Park (RTP), North Carolina, develops applications
for polymerase chain reaction (PCR) technology. Its Center for
Occupational Testing in RTP is the world's largest substance abuse
testing facility, and the Center for Esoteric Testing in Burlington,
North Carolina, performs the largest volume of rare analyses in the
network. LabCorp's clients include physicians, state and federal
governments, managed care organizations, hospitals, clinics, long-
term care facilities, companies, and other clinical laboratories.
###
_______________________________